Recent Advances in the Early Detection of Alzheimer's Disease
2017 SOCRA Annual Conference
Dorene Rentz, PsyD, Co-Dir, Center for Alzheimer's Research & Treatment, Brigham & Women's Hospital
With the advent of in vivo amyloid and tau imaging, we know that 30% of all cognitively normal older adults harbor significant pathological burden consistent with the diagnosis of Alzheimer’s disease (AD). Identified as preclinical AD, these underlying pathophysiological changes are occurring 15-20 years in advance of clinical symptoms. Dr. Rentz will discuss the theoretical concept of preclinical AD, the recent understanding of cognitive changes associated with biomarker evidence of preclinical AD, and current prevention strategies and treatment trials that are being implemented in the field.